Table 3.
Variables associated with presence/absence of liver steatosis in HIV monoinfected patients.
| Characteristics | No steatosis n = 67 | Steatosis n = 31 | Unadjusted PR (95% Cl)a | P univariate | Adjusted PR (95% Cl)a | P multivariate |
|---|---|---|---|---|---|---|
| Labs | ||||||
| Triglycerides (mg/dL)* | 148 (102–188) | 199 (147–243) | 1.00 (1.00–1.01) | <0.001 | 1.00 (1.00–1.01) | 0.012 |
| Total cholesterol (mg/dL) | 189 ± 33 | 187 ± 38 | 1.00 (0.90–1.01) | 0.709 | ||
| LDL cholesterol (mg/dL) | 107 ± 31 | 96 ± 30 | 1.00 (0.98–1.00) | 0.083 | ||
| HDL cholesterol (mg/dL)* | 46 (40–60) | 42 (35–53) | 0.99 (0.95–1.02) | 0.352 | ||
| AST (U/L)* | 21 (17–24) | 23 (20–29) | 1.01 (0.99–1.04) | 0.190 | ||
| ALT (U/L)* | 22 (15–27) | 28 (19–42) | 1.02 (1.01–1.03) | <0.001 | 1.15 (1.07–1.23) | 0.003 |
| Total bilirubin (mg/dL)* | 0.3 (0.3–0.6) | 0.7 (0.4–2.1) | 1.24 (1.02–1.50) | 0.027 | 2.02 (1.25–3.45) | 0.006 |
| Fibrosis markers | ||||||
| FIB-4 score* | 0.860 (0.630–1.220) | 0.910 (0.760–1.460) | 1.33 (1.08–1.64) | 0.007 | ||
| APRI score* | 0.197 (0.154–0.306) | 0.256 (0.198–1.385) | 3.42 (1.53–7.64) | 0.003 | ||
Median (IQR)*.
aPrevalence ratio and confidence intervals were estimated using Poisson regression.
Abbreviations: LDL, low density protein; HDL, high density protein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; FIB-4, fibrosis-4; APRI, AST to platelet ratio index; PR, prevalence ratio; CI, confidence interval.